**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 47640

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Liquid biopsy for non-invasive assessment of liver injury in hepatitis B patients**

Xia WY *et al*. Liquid biopsy for liver injury

Wen-Ying Xia, Li Gao,Er-Hei Dai, Dan Chen, Er-Fu Xie, Li Yang, Shi-Chang Zhang, Bing-Feng Zhang, Jian Xu, Shi-Yang Pan

**Wen-Ying Xia, Li Gao, Dan Chen, Er-Fu Xie, Shi-Chang Zhang, Bing-Feng Zhang, Jian Xu, Shi-Yang Pan,** Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

**Er-Hei Dai, Li Yang,** Department of Laboratory Medicine, the Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, Hebei Province, China

**ORCID number:** Wen-Ying Xia (0000-0003-2359-1379); Li Gao (0000-0002-9762-448X); Er-Hei Dai (0000-0001-8835-6199); Dan Chen (0000-0003-1141-3890); Er-Fu Xie (0000-0002-6787-7646); Li Yang (0000-0002-8762-2923); Shi-Chang Zhang (0000-0002-6587-2518); Bing-Feng Zhang (0000-0003-0240-3447); Jian Xu (0000-0003-2032-251X); Shi-Yang Pan (0000-0001-9320-6988).

**Author contributions:** Xia WY, Gao L, and Dai EH contributed equally to this work as co-first authors and finished the major experiments; Pan SY designed the research; Chen D, Xie EF, and Yang L collected and analyzed the data; Gao L and Zhang SC wrote the paper; Zhang BF and Xu J critically revised the manuscript for important content.

**Supported by** the National Natural Science Foundation of China, No. 81672100 and No. 81371894; the Key Laboratory for Laboratory Medicine of Jiangsu Province of China, No. ZDXKB2016005; and Jiangsu Provincial Commission of Health and Family Planning, No. H201609.

**Institutional review board statement:** This study was approved for publication by our Institutional Reviewer.

**Informed consent statement:** All study participants or their legal guardian provided informed written consent for personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** All authors have no conflict of interest related to the manuscript.

**Data sharing statement:** The original anonymous dataset is available on request from the corresponding author at [sypan@njmu.edu.cn](mailto:sypan@njmu.edu.cn).

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Shi-Yang Pan, MD, Professor,** Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing 210029, Jiangsu Province, China. [sypan@njmu.edu.cn](mailto:sypan@njmu.edu.cn)

**Telephone:** +86-25-68303452

**Received:** March 26, 2019

**Peer-review started:** March 26, 2019

**First decision:** May 24, 2019

**Revised:** June 13, 2019

**Accepted:** July 5, 2019

**Article in press:** July 5, 2019

**Published online:** August 7, 2019

**Abstract**

***BACKGROUND***

Hepatitis B is a major public health problem in China. Accurate liver injury assessment is essential for clinical evidence-based treatment. Liver biopsy is considered the gold standard method to stage liver disease, but it is not widely used in resource-limited settings. Therefore, non-invasive liquid biopsy tests are needed.

***AIM***

To assess liver injury in hepatitis B patients using quantified cell free DNA combined with other serum biomarker as a liquid biopsy-based method.

***METHODS***

A cohort of 663 subjects including 313 hepatitis B patients and 350 healthy controls were enrolled. Ultrasound-guided liver biopsies followed by histopathological assessments were performed for the 263 chronic hepatitis B patients to determine the degree of liver injury. Cell-free DNA was quantified using a novel duplex real-time polymerase chain reaction assay.

***RESULTS***

Compared with healthy controls, patients with hepatitis B virus (HBV) infection had significantly higher plasma DNA, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and HBV DNA levels (*P* < 0.01). Serum ALT, AST, bilirubin, and plasma DNA levels of patients with marked-severe inflammation were significantly higher than those with mild-moderate inflammation (*P* < 0.01). There was a statistically significant correlation between hepatocyte inflammation severity and serum bilirubin (*R2* = 0.673, *P* < 0.01) or plasma DNA (*R2* = 0.597, *P* < 0.01) levels. The areas under the curves of serum ALT, bilirubin, plasma DNA, and their combination to distinguish between patients with mild–moderate and marked-severe inflammation were 0.8059, 0.7910, 0.7921, and 0.9564, respectively.

***CONCLUSION***

The combination of plasma DNA, serum ALT, and bilirubin could be a candidate liquid biopsy for non-invasive assessment of liver injury in hepatitis B patients.

**Key words:** Liquid biopsy; plasma DNA; Hepatitis B; Alanine aminotransferase; Duplex real-time quantitative polymerase chain reaction

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Our study used quantified cell free DNA combined with other serum biomarker as a liquid biopsy-based method to assess liver injury in hepatitis B patients. A cohort of 663 subjects including 313 hepatitis B patients and 350 healthy controls were enrolled. Ultrasound-guided liver biopsies followed by histopathological assessments were performed for the 263 chronic hepatitis B patients to determine the degree of liver injury. Cell-free DNA was quantified using a novel duplex real-time polymerase chain reaction assay. Our results demonstrated that the combination of plasma DNA, serum alanine aminotransferase, and bilirubin could be a candidate liquid biopsy for non-invasive assessment of liver injury in hepatitis B patients.

**Citation**: L, Dai EH, Chen D, Xie EF, Yang L, Zhang SC, Zhang BF, Xu J, Pan SY. Liquid biopsy for non-invasive assessment of liver injury in hepatitis B patients. *World J Gastroenterol* 2019; 25(29): 3985-3995 Available from:

**URL**: https://www.wjgnet.com/1007-9327/full/v25/i29/3985.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v25.i29.3985

**INTRODUCTION**

The liver, playing an important role in many bodily functions from protein production and blood clotting to cholesterol, glucose, and iron metabolism, is the most important detoxification organ in human body[[1](#_ENREF_1)]. Because of this, the liver becomes the vulnerable organ to be injured in various kinds of diseases, including pathogen infection, inherited metabolic disease, alcoholic hepatitis, drug-induced liver disease, autoimmune liver disease, and fatty liver disease. In clinical practice, accurate liver injury assessment is necessary for the evidence-based treatment.

Liver biopsy, which is thought to be the gold standard method for the assessment of liver injury severity, has been used to ascertain the degree of necroinflammation and fibrosis[[1](#_ENREF_1)]. Unfortunately, liver biopsy is not always an available option for many patients with liver disease. It is also impractical to monitor the disease by frequent biopsy. Blood biomarkers, such as liver aminotransferases and bilirubin, are the routine assessments as liquid biopsy to monitor patients and to guide clinical treatment[[1](#_ENREF_1)]. However, it is widely known that the degree of liver injury is quite different in various types of liver diseases. It is also thought that serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) concentrations are not necessarily a reliable index of hepatocyte necrosis, and this is especially seen in massive hepatic necrosis[[2](#_ENREF_2)]. To assess liver injury more accurately, more reliable biomarkers for liquid biopsy are required.

In this study, we focused on hepatitis B caused by the hepatitis B virus (HBV) which is a DNA virus that infects the liver. There are approximately two billion people exposed toHBV and more than 350 million chronically infected people worldwide[[3](#_ENREF_3), [4](#_ENREF_4)]. Hepatitis B is a major public health problem worldwide, especially in China[[5](#_ENREF_5)]. HBV infection can be either asymptomatic or symptomatic depending on the severity of liver injury, which is important for patients’ outcome and to help guide the choice of clinical therapy. The aim of the present study was to quantify cell released DNA, a sensitive biomarker for cell death assessment, in hepatitis B patients using the duplex real-time quantitative polymerase chain reaction (PCR) to explore its potential use as a liquid biopsy-based biomarker combined with other liver function tests for assessment of liver injury.

**MATERIALS AND METHODS**

***Patients and clinicopathological characteristics***

This study included a total of 313 HBV-infected patients (median age, 36 years; range, 12-78 years; 89 females) with chronic (*n* = 263) or acute (*n* = 50) infection. Chronic HBV infection was defined as a continuous positive hepatitis B surface antigen (HBsAg) test result for more than 6 months, while acute HBV infection was a positive HBsAg test result for less than 6 months. Clinical information including demographic characteristics was obtained from the patients’ medical records. Healthy volunteers (*n* = 350; median age, 36 years; range, 18-72 years; 100 females) who attended the First Affiliated Hospital of Nanjing Medical University for an annual health check-up were recruited as a control group.

***Liver biopsy***

Ultrasound-guided liver biopsies followed by histopathological assessment were performed for the 263 chronic HBV infected patients to determine the degrees of liver injury including inflammation (grade) and fibrosis (stage) according to the Grading and Staging System in China[[6](#_ENREF_6)], which was established based on the Ishak system[[7](#_ENREF_7)]. In this study, mild or moderate portal area inflammation and spotty or piecemeal necrosis without bridging and multi-acinar necrosis were categorized as mild–moderate inflammation, while marked portal area inflammation, marked spotty or piecemeal necrosis, and/or bridging and multi-acinar necrosis were categorized marked-severe inflammation. The fibrosis stages range from 0 to 4, where Stage 0 is for no fibrosis, Stage 1 for portal fibrosis without septa, Stage 2 for portal fibrosis with few septa, Stage 3 for numerous septa without cirrhosis, and Stage 4 for cirrhosis.

***Blood sample collection and processing***

After informed consent was obtained and the research protocol was approved by the Ethics Committee of Nanjing Medical University, a 2-mL peripheral blood sample was collected into an ethylenediamine tetraacetic acid-containing tube from each participant at the time of preliminary diagnosis. All of the blood samples were centrifuged (1600 *g*, 10 min) within 2 h after collection and plasma was carefully transferred into EP tubes. After an additional centrifugation at 16000 *g* for 10 min, 200 µL of plasma supernatant without blood cells was collected and 5 × 104 copiesof recombinant internal standard plasmid DNA were added as described previously[[8](#_ENREF_8)]. The mixed samples were stored at -80 °C until further processing. Serum samples were recovered from serum-separator tubes following centrifugation of whole blood at 3000 *g* for 10 min at room temperature.

***Plasma DNA extraction and quantification***

DNA was extracted from the 200 µL plasma samples containing the internal standard using the BILATEST DNA/RNA kit (BILATEC, Viernheim, Germany), following the manufacturer’s recommendations. After DNA extraction, duplex real-time PCR was performed for both the human β–actin gene and the internal control recombinant plasmid DNA in the same tube. Duplex ampliﬁcation curves were analyzed with Sequence Detection System Software (Ver. 1.4, Applied Biosystems). Specific probes and primers were described in our previous report[8].

***Detection of other serum biomarkers***

The routine clinical chemistry panel, including ALT, AST, bilirubin, and albumin was measured on an automatic biochemistry analyzer (AU5800, Beckman-Coulter, United States). Serum HBV DNA was quantified by real-time PCR assay (ABI7500, Applied Biosystem, United States). ALT and AST activities were measured using the recommended IFCC method. Bilirubin was measured using the vanadic acid oxidation method. Albumin was measured usingthebromocresol green colorimetry method. Serum HBV DNA was extracted using an HBV nucleic acid quantitative detection kit (KHB, China) and quantified by real-time PCR assay (ABI7500, Applied Biosystem, United States).

***Statistical analysis***

Results are presented as the median and interquartile range. Data were analyzed using the Kruskal–Wallis rank test and Mann–Whitney *U* test. Spearman’s rank correlation was performed to estimate the correlation between the degree of liver injury and plasma DNA, serum ALT, or bilirubin, respectively. The area under receiver operator characteristic (ROC) curve (AUC) was calculated to evaluate the diagnostic efficacy. All of these data were analyzed using Stata 9.2 software (Stata Corporation, College Station, TX, United States). A *P*-value < 0.05 was considered statistically significant.

**RESULTS**

***Serum ALT, AST, bilirubin, albumin, plasma DNA, and HBV DNA levels in healthy controls and HBV-infected patients***

The concentrations of serum ALT, AST, bilirubin, albumin, total plasma DNA, and HBV DNA in healthy controls and patients with HBV infection are shown in Table 1. There were statistically significant differences in serum ALT, AST, and plasma DNA levels between healthy males and females (*P* < 0.01). Healthy controls with a history of drinking alcohol had higher serum ALT, AST, bilirubin, and plasma DNA levels than those who rarely drank alcohol (*P* < 0.01).

Compared with healthy controls, patients with HBV infection had significantly higher plasma DNA, serum ALT, AST, bilirubin, HBV DNA levels, and lower serum albumin levels (*P* < 0.01). There were no statistically significant differences in the six blood-based biomarkers between patients with different sex or drinking history (*P* > 0.05). Although there were significant differences in serum ALT and HBV DNA levels between patients younger and older than 36 years, the Spearman’s rank correlation analysis showed that there were no statistical correlations between patient age and the blood-based biomarkers. Serum HBV DNA levels in HBeAg positive patients were significantly higher than those with negative HBeAg results (*P* < 0.01).

***Quantification of serum ALT, AST, bilirubin, albumin, total plasma DNA, and HBV DNA for assessment of liver injury in patients with chronic HBV infection***

As shown in Table 2, serum ALT, AST, bilirubin, and plasma DNA levels of patients with marked-severe inflammation were significantly higher than those of patients with mild–moderate inflammation (*P* < 0.01). However, serum ALT or AST levels of 42 patients with severe liver injury were lower than those of patients with marked inflammation. There was no statistically significant difference in serum HBV DNA or albumin levels between patients with mild–moderate and marked-severe inflammation (*P* > 0.05). The positive correlation between serum ALT and inflammation severity was statistically significant but weak (*R2* = 0.214, *P* < 0.01; Figure 1A) because the severe patients had low ALT levels. Inflammation severity determined by liver biopsy was correlated with serum bilirubin (*R2* = 0.673, *P* < 0.01; Figure 1B) and plasma DNA (*R2* = 0.597, *P* < 0.01; Figure 1C), but had no statistically significant correlation with HBV DNA (*R2* = 0.004, *P* = 0.281; Figure 1D).

As shown in Figure 2, the AUC of using plasma DNA to distinguish between patients with mild–moderate and marked-severe inflammation was 0.7921, which was similar to the AUCs of using serum ALT and bilirubin (0.8059 and 0.7910). The AUCs of using serum AST, albumin, and HBV DNA to distinguish between patients with mild-moderate and marked-severe inflammation were 0.6530, 0.4877, and 0.4952, respectively. After the combination of serum ALT, bilirubin, and plasma DNA (blue), there was a statistically significant increase of AUC (0.9564). There was also a significant difference in plasma DNA levels or bilirubin between patients with and without cirrhosis (*P* < 0.01), but there was no difference in serum ALT, AST, albumin, or HBV DNA (*P* > 0.05; Table 2).

As shown in Figure 3A, there was no statistically significant correlation between plasma DNA and serum ALT (*R2* = 0.012, *P* = 0.08). Most of the patients with high serum ALT levels (>100.0 U/L) had marked-severe liver injury (red), suggesting a high specificity (89.3%) and positive predictive value (84.0%). However, there were still 33.5% of patients with low serum ALT levels (≤100.0 U/L) who had marked-severe liver injury, which suggests a low sensitivity (55.3%) of serum ALT. For example, patient 85 in Figure 3A was a 20-year-old man with chronic hepatitis B (CHB). Laboratory studies showed an HBV DNA level of 2.04 × 107 IU/mL and an ALT level of only 40 U/L. However, a needle biopsy of the liver showed severe piecemeal necrosis (marked portal inflammation, Grade 3; Figure 3B). These false negative patients could be further distinguished from patients with mild–moderate inflammation by plasma DNA with a sensitivity of 97.5% and specificity of 68.6% at the cutoff value of 95 ng/mL, as shown in Figure 3A. After the combination of serum ALT, bilirubin, and plasma DNA, there was a statistically significant increase in AUC (0.9564), with a maximum sensitivity and specificity of 88.64% and 80.15%, respectively (the blue line in Figure 2).

***Comparison of serum ALT, AST, bilirubin, albumin, total plasma DNA, and HBV DNA levels in patients with chronic or acute HBV infection***

Serum ALT, AST, bilirubin, albumin, total plasma DNA, and HBV DNA levels in patients with chronic or acute HBV infection are shown in Table 2. There was no statistically significant difference in HBV DNA levels between patients with chronic and acute HBV infection (*P* > 0.05). However, total plasma DNA, bilirubin, serum ALT, AST, and albumin levels in patients with acute HBV infection were significantly higher than those of patients with chronic HBV infection (*P* < 0.01). ROC curve analysis showed that the AUC of using serum ALT levels to distinguish between patients with chronic and acute HBV infection was 0.8702, which was significantly higher than that of using plasma DNA (0.7800; *P* = 0.01).

**DISCUSSION**

Hepatitis B is a viral infectious disease caused by the HBV which primarily interferes with the functions of the liver by replicating in hepatocytes[[5](#_ENREF_5)]. During HBV infection, the host immune response causes both viral clearance and hepatocellular damage[[9](#_ENREF_9)]. In clinical practice, hepatitis B patients usually need to undergo a liver biopsy, which is the current gold standard method for liver injury assessment by direct cell morphological observation[[1](#_ENREF_1), [10](#_ENREF_10)]. However, biopsy results are too dependent on the representation of the punctured sample and show significant variability which can lead to a wrong diagnosis[[11](#_ENREF_11)]. Besides, liver biopsy requires a skilled expert and well-equipped hospital, and still has the risk of potentially lethal complications, such as pneumothorax and bleeding[[12](#_ENREF_12)]. Therefore, liver biopsy is not always the best option for monitoring disease and some other more reliable techniques to assess liver injury, such as liquid biopsy focusing on biomarkers in body fluids, are required.

HBV infection can stimulate the body to produce various kinds of cell and humoral immunity responses to virus antigens and lead to persistent or massive hepatocellular apoptosis and necrosis[[9](#_ENREF_9), [13](#_ENREF_13), [14](#_ENREF_14)]. As a result of cell damage, the components of liver cells including proteins and nucleic acids are released into the peripheral blood stream. This could increase the reference values and the quantitative detection of these substances released from damaged liver cells into body fluids may serve as a noninvasive liquid biopsy to evaluate and monitor hepatitis-related liver damage[[15](#_ENREF_15)].

Liver-specific enzymes such as ALT and AST are the most common serum biomarkers for liver function assessment[[16](#_ENREF_16)]. However, the point of using ALT or AST for liver cell injury assessment remains controversial. Desmet *et al*[[17](#_ENREF_17)] found that the serum ALT level rose in almost all chronic liver diseases, yet this marker could not reliably reflect the degree of inflammatory injury. Kew suggested that serum ALT was not a reliable indicator in extensive hepatic necrosis in severe hepatitis, when decreasing serum ALT concentrations might signify a paucity of hepatocytes from which the enzymes could leak, rather than recovery[[2](#_ENREF_2)]. Our current findings also demonstrate that serum ALT and AST levels are not always correlated with hepatocyte inflammation, especially in the patients with severe hepatocyte injury (Figure 1). The sensitivity of serum ALT or AST is less than 60%, which will lead to missed diagnosis and delay in clinical treatment.

Circulating plasma DNA, a kind of cell-free extracellular nucleic acid present in normal healthy individuals at low concentrations, is believed to derive primarily from apoptosis of normal cells[[18](#_ENREF_18)]. The short half-life of plasma DNA in the circulation suggests a model of continuous release from apoptotic cells and rapid clearance[[19](#_ENREF_19)]. In the context of various disease states characterized by abnormal cell death, such as cancer, trauma, and transplant rejection, a large amount of nucleic acids are released from necrotic cells into blood stream and significantly increase the level of plasma DNA[[20-26](#_ENREF_20)]. Although plasma DNA quantification was proved to be a potential marker for cell damage, various preanalytical factors and lack of accurate and precise quantitative methods have become a considerable pitfall, hampering its application for liver injury assessment in clinical laboratories. In our previous study, a duplex real-time PCR assay with a novel internal standard was developed for plasma DNA quantification and proved to be able to eliminate variations and allow for more sensitive, repeatable, accurate, and stable quantitative measurements of plasma DNA[[8](#_ENREF_8)].

In the current study, we quantified total plasma DNA in 350 healthy controls and 313 HBV infected patients by using our novel assay, combined with several other serum biomarkers, to develop a novel liquid biopsy for non-invasive assessment of liver injury. Among healthy controls, higher serum ALT, AST, and plasma DNA levels were found in males and people with a history of drinking alcohol. While males have a higher basal metabolic rate than females, a higher activity rate of liver cells can lead to more ALT, AST, and genomic DNA released from apoptotic liver cells into the blood[[27](#_ENREF_27)]. Drinking alcohol causes mild hepatocellular damage, which can lead to hepatocyte necrosis followed by ALT, AST, and genomic DNA release. We also demonstrated that HBV infected patients had statistically significantly higher serum ALT, AST, and total plasma DNA levels than healthy controls.

In 263 CHB patients with varying degrees of liver injury, we demonstrated statistically significantly higher serum ALT, AST, bilirubin, albumin, total plasma DNA, and HBV DNA levels than those of healthy controls. We then compared these blood-based biomarker levels in patients with different degrees of liver injury according to liver biopsy. While HBV is a noncytopathic virus and its replication does not directly damage the liver cells, the degree of hepatocyte injury has no direct correlation with the number of HBV DNA copies[[28](#_ENREF_28)]. In this study, the HBV DNA level did not reflect the severity of liver injury in hepatitis B patients (Table 2). As to serum ALT, it had a high specificity (89.3%) but low sensitivity (55.3%) to discriminate between mild–moderate and marked-severe inflammation. Similar results were found for serum AST. This suggests that nearly half of patients, which were diagnosed with severe liver injury based solely on serum ALT or AST levels, may be misdiagnosed (*e.g*., patient 85 in Figure 3). By using our novel duplex real-time PCR assay with internal standard, it was demonstrated that plasma DNA concentration was more correlated with the severity of hepatocyte injury than serum ALT levels (Figure 1) and more sensitive to assess the severity of liver injury in patients with low serum ALT (≤100.0 U/L; Figure 3A). Cell-free plasma DNA, a superior indicator of cell death, was shown to be a good complement to serum aminotransferases to improve sensitivity. It has been estimated that when 1% of liver cells are damaged, enzymes such as ALT are released into the peripheral blood and this could increase the reference value about one-fold. Considering that 1% of genomic DNA out of the total 2500000000 liver cells is released into plasma, the concentration of plasma DNA would increase by approximate 66 ng/mL, which is 2.6-fold higher than the median value of healthy people. Here, we suggest that this might be an explanation for the effectiveness of plasma DNA in assessing the severity of liver injury in patients with low serum ALT. However, because of the low specificity (68.6%), plasma DNA alone is not sufficient to evaluate hepatic cell injury. After the combination of plasma DNA, serum ALT, and bilirubin, there was a significant improvement in AUC (Figure 2).

Because of the invasiveness and risk of complications, there are many limitations for liver biopsy in clinical practice. Certain conditions, including thrombocytopenia, bleeding diathesis, cirrhosis, ascites, and amyloidosis, are recognized relative or absolute contraindications to biopsy[[29](#_ENREF_29)]. Therefore, noninvasive liquid biopsy is the necessary and useful substitution for patients who are not suitable to undertake liver biopsy. According to the WHO’s guidelines[[1](#_ENREF_1)], there are several non-invasive tests (NITs) based on blood or serum now available and increasingly used for evaluating and staging liver fibrosis. However, except for serum ALT, AST, and bilirubin, few new NITs has been developed for assessment of liver injury, which can reduce the need for liver biopsy in persons with hepatitis B. In this study, by quantifying serum ALT and plasma DNA, clinicians can assess the severity of liver injury and evaluate the patient's condition to determine the best course of treatment. For example, as shown in Figure 4, low levels of serum ALT, bilirubin, and plasma DNA indicate that there is no significant liver injury, while persistent high level of plasma DNA combined with elevated bilirubin can indicate the severity of hepatocellular injury in the case of severe liver cell damage with the “enzyme bilirubin separate” phenomenon. Furthermore, liquid biopsy can be repeated and present a dynamic change throughout the clinical treatment. But as to liver biopsy, that is impossible. This liquid biopsy for non-invasive assessment of liver injury in hepatitis B patients may be an important supplement be written into the guideline in the future. It is also believed that this kind of non-invasive liquid biopsy can be applied for liver injury assessment in many other liver diseases besides hepatitis B.

This is believed to be the first study about combination of plasma DNA, serum ALT, and bilirubin as a sensitive and unique liquid biopsy for the noninvasive assessment of degree of liver injury. This novel liquid biopsy technique is expected to assist in making more precise diagnoses for hepatitis B patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatitis B is a major public health problem in China. It is important that the severity of liver injury is evaluated accurately for clinical treatment. Liver biopsy is considered the gold standard method to stage liver disease. However, it is not widely used in resource-limited settings. Therefore, the methods of non-invasive liquid biopsy need to be explored for assessment of liver injury.

***Research motivation***

Plasma DNA quantification was proved to be a potential marker for cell damage, which may be a non-invasive method for evaluating the severity of liver injury. However, the application of plasma DNA quantification still needs to be investigated in patients with hepatitis B.

***Research objectives***

The aim of this study was to evaluate liver injury in hepatitis B patients using quantified cell free DNA combined with other serum biomarker as a liquid biopsy-based method.

***Research methods***

A cohort of 663 subjects including 313 hepatitis B patients and 350 healthy controls were enrolled. Ultrasound-guided liver biopsies followed by histopathological assessments were performed for the 263 chronic hepatitis B patients to determine the degree of liver injury. Cell-free DNA was quantified using a novel duplex real-time polymerase chain reaction assay.

***Research results***

Compared with healthy controls, patients with hepatitis B virus (HBV) infection had significantly higher plasma DNA, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and HBV DNA levels (*P* < 0.01). Serum ALT, AST, bilirubin, and plasma DNA levels of patients with marked-severe inflammation were significantly higher than those of patients with mild-moderate inflammation (*P* < 0.01). There was a statistically significant correlation between hepatocyte inflammation severity and serum bilirubin (*R2* = 0.673, *P* < 0.01) or plasma DNA (*R2* = 0.597, *P* < 0.01) levels. The area under the curves of serum ALT, bilirubin, plasma DNA, and their combination to distinguish between patients with mild–moderate and marked-severe inflammation were 0.8059, 0.7910, 0.7921, and 0.9564, respectively.

***Research conclusions***

The combination of plasma DNA, serum ALT, and bilirubin could be a candidate liquid biopsy for non-invasive assessment of liver injury in hepatitis B patients.

***Research perspectives***

The combination of plasma DNA, serum ALT, and bilirubin as a novel liquid biopsy technique is expected to assist in making more precise diagnoses for hepatitis B patients, which will be validated in multiple clinical centers in the future.

**REFERENCES**

1 Geneva: World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. 2015 [PMID: 26225396]

2 **Kew MC**. Serum aminotransferase concentration as evidence of hepatocellular damage. *Lancet* 2000; **355**: 591-592 [PMID: 10696975 DOI: 10.1016/S0140-6736(99)00219-6]

3 **Schweitzer A**, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. *Lancet* 2015; **386**: 1546-1555 [PMID: 26231459 DOI: 10.1016/S0140-6736(15)61412-X]

4 **Ott JJ**, Horn J, Krause G, Mikolajczyk RT. Time trends of chronic HBV infection over prior decades - A global analysis. *J Hepatol* 2017; **66**: 48-54 [PMID: 27592304 DOI: 10.1016/j.jhep.2016.08.013]

5 **Lao TT**, Sahota DS, Law LW, Cheng YK, Leung TY. Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China. *Bull World Health Organ* 2014; **92**: 782-789 [PMID: 25378739 DOI: 10.2471/BLT.13.133413]

6 **Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association**. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2011; **32**: 405-415 [PMID: 21569677 DOI: 10.3760/cma.j.issn.0254-6450.2011.04.019]

7 **Ishak K**, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995; **22**: 696-699 [PMID: 7560864 DOI: 10.1016/0168-8278(95)80226-6]

8 **Chen D**, Pan S, Xie E, Gao L, Xu H, Xia W, Xu T, Huang P. Development and Evaluation of a Duplex Real-Time PCR Assay With a Novel Internal Standard for Precise Quantification of Plasma DNA. *Ann Lab Med* 2017; **37**: 18-27 [PMID: 27834061 DOI: 10.3343/alm.2017.37.1.18]

9 **Shin EC**, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. *Nat Rev Immunol* 2016; **16**: 509-523 [PMID: 27374637 DOI: 10.1038/nri.2016.69]

10 **Mani H**, Kleiner DE. Liver biopsy findings in chronic hepatitis B. *Hepatology* 2009; **49**: S61-S71 [PMID: 19399798 DOI: 10.1002/hep.22930]

11 **Regev A**, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002; **97**: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]

12 **Lidbury JA**. Getting the Most Out of Liver Biopsy. *Vet Clin North Am Small Anim Pract* 2017; **47**: 569-583 [PMID: 28081862 DOI: 10.1016/j.cvsm.2016.11.007]

13 **Ganem D**. Persistent infection of humans with hepatitis B virus: Mechanisms and consequences. *Rev Infect Dis* 1982; **4**: 1026-1047 [PMID: 6293033 DOI: 10.1093/clinids/4.5.1026]

14 **Ganem D**, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. *N Engl J Med* 2004; **350**: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087]

15 **Schütz E**, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, Oellerich M. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. *PLoS Med* 2017; **14**: e1002286 [PMID: 28441386 DOI: 10.1371/journal.pmed.1002286]

16 **Giannini EG**, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. *CMAJ* 2005; **172**: 367-379 [PMID: 15684121 DOI: 10.1503/cmaj.1040752]

17 **Desmet VJ**, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. *Hepatology* 1994; **19**: 1513-1520 [PMID: 8188183 DOI: 10.1002/hep.1840190629]

18 **Chan AK**, Chiu RW, Lo YM; Clinical Sciences Reviews Committee of the Association of Clinical Biochemists. Cell-free nucleic acids in plasma, serum and urine: A new tool in molecular diagnosis. *Ann Clin Biochem* 2003; **40**: 122-130 [PMID: 12662399 DOI: 10.1258/000456303763046030]

19 **Lo YM**, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. *Am J Hum Genet* 1999; **64**: 218-224 [PMID: 9915961 DOI: 10.1086/302205]

20 **Sozzi G**, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U. Quantification of free circulating DNA as a diagnostic marker in lung cancer. *J Clin Oncol* 2003; **21**: 3902-3908 [PMID: 14507943 DOI: 10.1200/JCO.2003.02.006]

21 **Jiang T**, Zhai C, Su C, Ren S, Zhou C. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis. *Lung Cancer* 2016; **100**: 63-70 [PMID: 27597282 DOI: 10.1016/j.lungcan.2016.06.013]

22 **Bedin C**, Enzo MV, Del Bianco P, Pucciarelli S, Nitti D, Agostini M. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. *Int J Cancer* 2017; **140**: 1888-1898 [PMID: 27943272 DOI: 10.1002/ijc.30565]

23 **Lo YM**, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. *Clin Chem* 2000; **46**: 319-323 [PMID: 10702517 DOI: 10.1016/0049-3848(78)90297-9]

24 **Lam NY**, Rainer TH, Chan LY, Joynt GM, Lo YM. Time course of early and late changes in plasma DNA in trauma patients. *Clin Chem* 2003; **49**: 1286-1291 [PMID: 12881444 DOI: 10.1373/49.8.1286]

25 **Snyder TM**, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ transplant rejection. *Proc Natl Acad Sci U S A* 2011; **108**: 6229-6234 [PMID: 21444804 DOI: 10.1073/pnas.1013924108]

26 **Lui YY**, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. *Clin Chem* 2002; **48**: 421-427 [PMID: 11861434 DOI: 10.1016/S0009-9120(02)00282-5]

27 **Dufour DR**, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. *Clin Chem* 2000; **46**: 2027-2049 [PMID: 11106349 DOI: 10.1016/S0009-8981(00)00329-6]


28 **Liu X**, Chen JM, Lou JL, Huang YX, Yan Y, Sun GZ, Li N. Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B. *Genet Mol Res* 2016; **15** [PMID: 27421011 DOI: 10.4238/gmr.15028282]

29 **Grant A**, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. *Gut* 1999; **45**: IV1-IV11 [PMID: 10485854 DOI: 10.1136/gut.45.2008.iv1]


**P-Reviewer:** Demonacos C, Muench MO, Zapater P **S-Editor:** Yan JP

**L-Editor:** Wang TQ **E-Editor:** Ma YJ


**Specialty type:** Gastroenterology and hepatology   
**Country of origin:** China   
**Peer-review report classification**  
**Grade A (Excellent):** 0  
**Grade B (Very good):** B  
**Grade C (Good):** C, C  
**Grade D (Fair):** 0 **Grade E (Poor):** 0




**Figure 1 Correlations of blood biomarkers with severity of hepatocyte inflammation in 263 chronic hepatitis B patients.** The scatter plots show that there are statistically significant correlations between the severity of hepatocyte inflammation and levels of serum biomarkers. A: Alanine aminotransferase; B: Bilirubin; C: Plasma DNA; D: Hepatitis B virus DNA. ALT: Alanine aminotransferase; HBV: Hepatitis B virus.



**Figure 2 The receiver operator characteristic curves of using four blood biomarkers to assess hepatocellular injury severity in 263 chronic hepatitis B patients.** The areas under the curves (AUCs) of using serum alanine aminotransferase (ALT, black), bilirubin (yellow), plasma DNA (orange), serum aspartate aminotransferase (green), albumin (purple), and hepatitis B virus DNA (gray) to distinguish between patients with mild-moderate and marked-severe inflammation were 0.8059, 0.7910, 0.7921, 0.6530, 0.4877, and 0.4952, respectively. After the combination of serum ALT, bilirubin, and plasma DNA (blue), there was a statistically significant increase of AUC (0.9564). ALT: Alanine aminotransferase; HBV: Hepatitis B virus; AST: Aspartate aminotransferase; AUC: Area under the curve.



**Figure 3 Quantitative analysis of serum alanine aminotransferase and plasma DNA of 263 chronic hepatitis B patients to assess hepatocellular injury severity.** A: The scatter plot of serum alanine aminotransferase (ALT) and plasma DNA levels of chronic hepatitis B patients with mild-moderate (blue dots) or marked-severe (red dots) inflammation. Most (84.0%) of the patients with high serum ALT levels (>100.0 U/L) had marked-severe hepatocyte injury, while the other patients with marked-severe hepatocyte injury and low serum ALT levels (≤100.0 U/L) can be distinguished from patients with mild-moderate hepatocyte injury by plasma DNA quantification (*e.g.*, Case 85); B: The hematoxylin and eosin stained microscopic image (×400) of hepatic tissue of the case 85 showed severe piecemeal necrosis (marked portal inflammation) (Grade 3). ALT: alanine aminotransferase.



**Figure 4 Pattern diagram of liquid biopsy with serum alanine aminotransferase, bilirubin, and plasma DNA for assessment of hepatocellular injury in hepatitis B patients.** Serum alanine aminotransferase levels in patients with severe hepatocellular injury may not be very high and plasma DNA combined with serum bilirubin may be a good complementary biomarker for these patients. ALT: Alanine aminotransferase.

**Table 1 Correlation between clinicopathological characteristics and serum alanine aminotransferase, alanine aminotransferase, bilirubin, albumin, plasma DNA, or hepatitis B virus DNA levels in the 350 healthy controls and 313 patients**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Number of cases** |  | **Blood-based biomarkers** | | | | | | | | | | | | | | | | |
| **Serum ALT (U/L)** | ***P*** |  | **Bilirubin (μM)** | ***P*** |  | **Plasma DNA (ng/mL)** | ***P*** |  | **HBV DNA (IU/mL)** | ***P*** |  | **Serum AST (U/L)** | ***P*** |  | **Albumin**  **(g/L)** | ***P*** |
| **Healthy controls** | 350 |  | 19.1 (15.1) |  |  |  |  |  | 25.5 (17.6) |  |  | 0.0 (0.0) |  |  | 16.4 (14.3) |  |  | 46.0 (22.2) |  |
| **Sex** |  |  |  | <0.01 |  |  | 0.865 |  |  | <0.01 |  |  | --- |  |  | <0.01 |  |  | 0.062 |
| Male | 250 |  | 22.3 (14.1) |  |  | 10.6 (5.8) |  |  | 30.0 (16.1) |  |  | 0.0 (0.0) |  |  | 19.6 (14.1) |  |  | 46.4 (20.8) |  |
| Female | 100 |  | 12.6 (7.6) |  |  | 10.2 (5.5) |  |  | 16.7 (8.1) |  |  | 0.0 (0.0) |  |  | 10.1 (5.5) |  |  | 45.5 (20.1) |  |
| **Age (yr)** |  |  |  | 0.819 |  |  | 0.833 |  |  | 0.056 |  |  | --- |  |  | 0.916 |  |  | 0.066 |
| <36 | 175 |  | 18.9 (17.9) |  |  | 9.7 (5.4) |  |  | 23.6 (16.4) |  |  | 0.0 (0.0) |  |  | 16.0 (15.9) |  |  | 47.6 (20.3) |  |
| ≥36 | 175 |  | 19.8 (13.7) |  | 10.5 (5.7) |  |  | 26.8 (19.3) |  |  | 0.0 (0.0) |  |  | 16.7 (12.2) |  |  | 45.8 (23.4) |  |
| **HBsAb** |  |  |  | 0.263 |  |  | 0.439 |  |  | 0.060 |  |  | --- |  |  | 0.549 |  |  | 0.884 |
| Negative | 166 |  | 18.7 (15.1) |  |  | 10.3 (5.6) |  |  | 27.3 (19.1) |  |  | 0.0 (0.0) |  |  | 15.8 (15.1) |  |  | 45.7 (22.5) |  |
| Positive | 184 |  | 19.1 (15.0) |  | 10.3 (5.6) |  |  | 24.2 (16.0) |  |  | 0.0 (0.0) |  |  | 16.5 (15.2) |  |  | 46.2 (21.6) |  |
| **Drinking history** |  |  |  | <0.01 |  |  | 0.002 |  |  | 0.000 |  |  | --- |  |  | 0.000 |  |  | 0.711 |
| No | 278 |  | 18.6 (12.1) |  |  | 10.4 (5.7) |  |  | 22.8 (15.5) |  |  | 0.0 (0.0) |  |  | 15.8 (11.1) |  |  | 46.1 (20.9) |  |
| Yes | 72 |  | 34.1 (29.2) |  |  | 21.0 (19.2) |  |  | 38.3 (19.0) |  |  | 0.0 (0.0) |  |  | 33.5 (27.4) |  |  | 45.4 (23.7) |  |
| **Hepatitis B patients** | 313 |  | 103.3 (118.5) | <0.011 |  | 85.6 (77.2) | 0.0001 |  | 132.9 (253.7) | <0.011 |  | 6.1 (2.9) | <0.011 |  | 97.0 (101.6) | <0.011 |  | 42.7 (31.2) | <0.011 |
| **Sex** |  |  |  | 0.972 |  |  | 0.606 |  |  | 0.772 |  |  | 0.149 |  |  | 0.656 |  |  | 0.761 |
| Male | 224 |  | 101.4 (114.4) |  |  | 88.3 (91.6) |  |  | 134.2 (260.2) |  |  | 6.2 (2.7) |  |  | 95.3 (99.5) |  |  | 42.4 (32.7) |  |
| Female | 89 |  | 113.5 (143.8) |  |  | 82.9 (89.1) |  |  | 132.2 (170.7) |  |  | 5.6 (2.8) |  |  | 101.7 (116.6) |  |  | 43.0 (33.2) |  |
| **Age (yr)** |  |  |  | 0.011 |  |  | 0.221 |  |  | 0.312 |  |  | <0.01 |  |  | 0.831 |  |  | 0.591 |
| <36 | 155 |  | 89.2 (120.0) |  |  | 86.3 (90.4) |  |  | 135.9 (256.6) |  |  | 6.7 (3.0) |  |  | 96.5 (98.3) |  |  | 42.2 (30.4) |  |
| ≥36 | 158 |  | 115.9 (124.9) |  |  | 83.9 (91.5) |  |  | 115.8 (244.5) |  |  | 5.6 (2.6) |  |  | 97.8 (103.2) |  |  | 43.1 (29.7) |  |
| **HBeAg** |  |  |  | 0.236 |  |  | 0.173 |  |  | 0.833 |  |  | <0.01 |  |  | 0.742 |  |  | 0.070 |
| Negative | 159 |  | 109.7 (126.6) |  |  | 84.4 (89.4) |  |  | 126.3 (294.0) |  |  | 5.4 (3.1) |  |  | 97.7 (101.8) |  |  | 43.3 (32.5) |  |
| Positive | 154 |  | 101.4 (117.0) |  |  | 86.1 (90.7) |  |  | 135.7 (228.9) |  |  | 6.5 (2.3) |  |  | 97.4 (99.6) |  |  | 40.6 (34.6) |  |
| **Drinking history** |  |  |  | 0.487 |  |  | 0.577 |  |  | 0.574 |  |  | 0.200 |  |  | 0.433 |  |  | 0.654 |
| No | 187 |  | 107.0 (122.8) |  |  | 85.0 (87.3) |  |  | 126.3 (255.4) |  |  | 6.2 (2.7) |  |  | 95.8 (98.5) |  |  | 42.0 (30.8) |  |
| Yes | 126 |  | 100.6 (118.0) |  |  | 86.9 (90.3) |  |  | 142.8 (243.6) |  |  | 6.0 (3.0) |  |  | 98.3 (100.1) |  |  | 43.2 (30.7) |  |

1Compared with the healthy controls. All continuous data are expressed as medians (interquartile range). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBV: hepatitis B virus; HBsAb: Hepatitis B surface antibody; HBeAg: Hepatitis B E-antigen.

**Table 2 Serum alanine aminotransferase, alanine aminotransferase, bilirubin, albumin, plasma DNA, and serum hepatitis B virus DNA levels in different patient groups**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | | **Number of cases** |  | **Blood-based biomarkers** | | | | | | | | | | | | | | | | |
|  |  | **Serum ALT (U/L)** | ***P*** |  | **Bilirubin (μM)** | ***P*** |  | **Plasma DNA (ng/mL)** | ***P*** |  | **HBV DNA (IU/mL)** | ***P*** |  | **Serum AST (U/L)** | ***P*** |  | **Albumin**  **(g/L)** | ***P*** |
| **Healthy controls** | | 350 |  | 19.1 (15.1) |  |  |  |  |  | 25.5 (17.6) |  |  | 0.0 (0.0) |  |  | 16.4 (14.3) |  |  | 46.0 (22.2) |  |
| **Acute HBV infection** | | 50 |  | 213.8 (355.9) |  |  | 121.6 (207.0) |  |  | 336.8 (179.5) |  |  | 5.5 (2.4) |  |  | 197.6 (312.5) |  |  | 45.4 (24.6) |  |
| **Chronic HBV infection** | | 263 |  | 88.3 (98.0) | <0.011 |  | 73.9 (88.3) | <0.011 |  | 106.4 (174.1) | <0.011 |  | 6.2 (2.9) | 0.059\* |  | 90.6 (93.7) | <0.011 |  | 40.2 (41.3) | 0.0041 |
| **Inflammation** | |  |  |  | <0.01 |  |  | <0.01 |  |  | <0.01 |  |  | 0.893 |  |  | <0.01 |  |  | 0.444 |
| Mild | | 68 |  | 59.9 (41.5) |  |  | 30.6 (31.4) |  |  | 46.9 (29.5) |  |  | 5.7 (2.5) |  |  | 51.2 (50.6) |  |  | 41.7 (28.6) |  |
| Moderate | | 70 |  | 62.8 (68.0) |  |  | 45.4 (50.4) |  |  | 106.1 (127.2) |  |  | 6.4 (3.1) |  |  | 61.3 (72.9) |  |  | 40.9 (30.4) |  |
| Marked | | 83 |  | 152.8 (114.7) |  |  | 130 (125.5) |  |  | 141.1 (77.4) |  |  | 5.8 (2.8) |  |  | 153.2 (160.8) |  |  | 39.5 (32.6) |  |
| Severe | | 42 |  | 99.9 (148.0) |  |  | 228 (254.9) |  |  | 862.5 (1213.6) |  |  | 6.8 (2.8) |  |  | 91.7 (135.1) |  |  | 39.8 (33.2) |  |
| **Fibrosis** | |  |  |  | 0.552 |  |  | 0.015 |  |  | <0.01 |  |  | 0.060 |  |  | 0.121 |  |  | 0.606 |
| No cirrhosis | | 212 |  | 88.0 (106.4) |  |  | 65.2 (58.2) |  |  | 131.0 (235.8) |  |  | 6.3 (3.1) |  |  | 87.0 (93.0) |  |  | 40.8 (38.6) |  |
| Stage 0 | | 59 |  | 83.5 (98.6) |  |  | 71.9 (70.3) |  |  | 111.8 (477.0) |  |  | 6.6 (3.0) |  |  | 87.7 (91.6) |  |  | 41.6 (38.5) |  |
| Stage 1 | | 72 |  | 96.6 (81.2) |  |  | 60.2 (66.7) |  |  | 179.6 (235.3) |  |  | 6.5 (3.0) |  |  | 88.4 (90.3) |  |  | 40.1 (38.3) |  |
| Stage 2 | | 46 |  | 87.4 (89.0) |  |  | 64.8 (79.6) |  |  | 98.8 (90.1) |  |  | 6.0 (2.7) |  |  | 79.1 (82.5) |  |  | 40.1 (38.7) |  |
| Stage 3 | | 35 |  | 91.7 (110.3) |  |  | 77.7 (72.4) |  |  | 87.2 (77.7) |  |  | 6.0 (2.7) |  |  | 84.6 (88.0) |  |  | 40.2 (39.9) |  |
| Cirrhosis (Stage 4) | | 51 |  | 91.4 (73.5) |  |  | 92.0 (99.4) |  |  | 73.1 (44.8) |  |  | 5.7 (2.1) |  |  | 91.9 (94.5) |  |  | 39.9 (43.8) |  |

1Compared with the acute hepatitis B virus infection patients. All continuous data are expressed as medians (interquartile range). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBV: Hepatitis B virus.